DDL, a provider of package, product, and material testing services, announced on Monday the opening of a new Good Manufacturing Practice (GMP) laboratory for drug-device combination product testing.
This expansion enhances DDL's capacity to support the pharmaceutical, biotech and combination product industries with rigorous, regulatory-compliant testing solutions.
The new FDA-registered 10,600 sq ft GMP lab is located near DDL's headquarters in Eden Prairie, Minnesota. The lab will offer ICH stability testing, functional and mechanical performance testing (ISO 11040 & ISO 11608) and simulated distribution testing to meet the growing demand for high-quality GMP testing for devices such as auto injectors, pre-filled syringes, inhalers and other combination products.
DDL said that its new facility will provide comprehensive testing solutions in accordance with FDA, ISO and other global regulatory standards.
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Tristel secures FDA clearance for Ophthalmic Disinfectant Tristel OPH
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Coologics' seed funding round raises over USD3m
DDL opens new GMP laboratory for drug-device combination product testing
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Qlife secures UK approval to initiate clinical trial for Egoo Phe System